Cargando…

Lipid Lowering Drugs: Present Status and Future Developments

PURPOSE OF REVIEW: Based on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin lipid lowering approaches to reduce the cardiovascular burden in patients at highest risk. RECENT FINDINGS: For hypercholesterolemia, the small...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruscica, Massimiliano, Ferri, Nicola, Santos, Raul D., Sirtori, Cesare R., Corsini, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Statin Drugs (R. Ceska, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946696/ https://www.ncbi.nlm.nih.gov/pubmed/33694108 http://dx.doi.org/10.1007/s11883-021-00918-3

Ejemplares similares

The Role of High-Density Lipoprotein Cholesterol in 2022
por: Sirtori, Cesare R., et al.
Publicado: (2022)

The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia
por: Pang, Jing, et al.
Publicado: (2020)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease
por: Packard, Chris J.
Publicado: (2022)

Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents
por: Cohen, Hofit, et al.
Publicado: (2021)

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
por: Martin, Anna, et al.
Publicado: (2022)

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology
por: Altschmiedová, Tereza, et al.
Publicado: (2022)

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial
por: Lorgelly, Paula K., et al.
Publicado: (2010)

PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
por: Carugo, Stefano, et al.
Publicado: (2022)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

A Review of the Rationale for Additional Therapeutic Interventions to Attain Lower LDL-C When Statin Therapy Is Not Enough
por: Shanes, Jeffrey G.
Publicado: (2011)

Clinical approach to the inflammatory etiology of cardiovascular diseases
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Statin Intolerance: the Clinician’s Perspective
por: Stulc, Tomáš, et al.
Publicado: (2015)

Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
por: Lee, Matthew M. Y., et al.
Publicado: (2019)

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
por: Strandberg, Timo E.
Publicado: (2019)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Fixed Combination for the Treatment of Dyslipidaemia
por: Ferri, Nicola, et al.
Publicado: (2023)

Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis
por: Ruscica, Massimiliano, et al.
Publicado: (2019)

Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells
por: Macchi, Chiara, et al.
Publicado: (2021)

Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023)

Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Anti-Inflammatory and Gastroprotective Properties of Aspirin - Entrapped Solid Lipid Microparticles
por: Chime, Salome A., et al.
Publicado: (2020)

Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE(-/-) Mice
por: Macchi, Chiara, et al.
Publicado: (2022)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Meroni, Marica, et al.
Publicado: (2021)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Unravelling the health effects of fasting: a long road from obesity treatment to healthy life span increase and improved cognition
por: Wilhelmi de Toledo, Françoise, et al.
Publicado: (2020)

Use of statins after liver transplantation is associated with improved survival: results of a nationwide study
por: Becchetti, Chiara, et al.
Publicado: (2022)

Role of lipoprotein(a) in plaque progression
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

PPAR Agonists and Metabolic Syndrome: An Established Role?
por: Botta, Margherita, et al.
Publicado: (2018)

The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis
por: Jamialahmadi, Tannaz, et al.
Publicado: (2022)

Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges
por: Elbers, L.P.B., et al.
Publicado: (2016)

Updates in Small Interfering RNA for the Treatment of Dyslipidemias
por: Carugo, S., et al.
Publicado: (2023)

Evaluation of Transthoracic Echocardiography in the Assessment of Atherosclerosis of the Left Main Coronary Artery: Comparison with Optical Frequency Domain Imaging (a Pilot Study)
por: Labombarda, Fabien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sttucmod41r6och4l18lmrbc49